Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Quantifying Atrial Fibrillation Burden to inform Screening, Treatment, and hEalth Policy

Project description

Implanted devices to identify the impacts of atrial fibrillation

Atrial fibrillation (AF) affects one in three people over 55 and leads to serious health issues. Current binary diagnosis limits understanding of AF’s impact, causing anxiety from brief detections. Better quantification can enhance detection and improve health outcomes. The EU-funded AF-B-STEP project aims to identify how the burden of AF impacts health outcomes in patients using implanted devices and monitors. By analysing data from over 100 000 patients, the project will quantify the contributions of AF burden to health issues such as stroke and heart failure. It will establish universal reporting standards and actionable thresholds for AF burden, providing crucial data to improve clinical care and support treatment innovation.

Objective

Atrial fibrillation (AF) affects every 3rd 55 year-old and causes severe death and severe morbidity, especially stroke and heart failure. AF consumes 2-3% of total healthcare cost in Europe. AF is currently diagnosed in a binary (yes/no) fashion. This has critical limitations, illustrated by low event rates in AF screening trials and in device-detected AF. This creates avoidable uncertainty and anxiety when implanted devices and consumer electronics detect short and rare episodes of AF in real-time. Quantification of AF burden and knowledge on its relation to outcomes can resolve this and harness the health opportunities of consumer-led AF detection. AF-B-STEP will define which AF burden affects health outcomes in patients with AF for implanted devices and intermittent rhythm monitors. This will improve clinical care and facilitate AF innovations.
In AF-B-STEP, a public-private partnership, academia, industry, patients and payors work hand-in-glove with device, drug, and m-health industry. Integration of patient voices, health economics, an international external steering committee and of the European Medicines Agency and the FDA ensure high impact and rapid implementation. Multiple large, well-phenotyped, data sets containing AF burden and health outcomes from over 100,000 patients will be combined. This data set will be used to quantify AF burden and to define which AF burden contributes to stroke, heart failure, cardiovascular death and to patient-reported outcomes, cardiac and cognitive function. AF burden-reducing randomized trials will be analysed to validate these effects and to estimate actionable AF burden thresholds. We will define universally applicable standards for the reporting of AF burden by implanted devices and by consumer electronics. Key markers for low and high AF burden will be defined and validated. The project will provide robust data on the impact of AF burden on health. This will enable regulators, guideline writers, clinicians and innovators to integrate AF burden into their work.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-IHI-2025-09-single-stage

See all projects funded under this call

Coordinator

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Net EU contribution
€ 2 462 000,00
Address
Martinistrasse 52
20251 Hamburg
Germany
Region
Hamburg Hamburg Hamburg
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 462 000,00

Participants (17)